Chengdu, China, January 9 – With the approval of the Board of Directors of Chengdu New Radiopharmaceutical Co., Ltd. (“NRT”), NRT announced the appointment of Dr. Qingxian Kong as Chief Medical Officer.

Dr. Qingxian Kong will be Chief Medical Officer of NRT and concurrently, Deputy General Manager of NRT Biopharmaceutical (Sichuan) Co., Ltd. He will be leading NRT clinical strategy development and the overall management of clinical activities.

Dr. Qingxian Kong received his medical degree from Shanghai Medical College of Fudan University and his Postdoc training in Medical Oncology from Roswell Park Cancer Center, USA. Dr. Kong has years of practice experience in radiotherapies and more than 20 years of management experience in the fields of medical and clinical development with global pharmaceutical companies. He was a radiation oncologist at Fudan Cancer Hospital in Shanghai and served as Medical Affairs Manager at Schering-Plough, Research Team Leader at Roche Clinical Programs, Medical Director at Bayer (hematological malignancies), Senior Medical Director at SUNKI, and Head of Global Medical Affairs at Novartis for ribociclib (CDK4/6 inhibitor) and alpelisib (α-PI3K inhibitor). He also took senior positions as Vice President of Clinical Oncology at Jiangsu Hengrui Pharmaceutical Co., Ltd., Chief Medical Officer and Corporate Vice President at Qilu Pharmaceuticals, and Chief Medical Officer of Reindeer Medical. He is familiar with regulatory strategies of China Center for Drug Evaluation (CDE) and U.S. FDA, and global novel drug development. Dr. Kong has rich professional experience in the fields of oncology, immunology, and hematology, and global clinical development of innovative drugs and biosimilars.

 NRT has received several IND approvals by China CDE and U.S. FDA. We believe Dr. Kong will bring strong support to NRT clinical development, and medical leadership in radiopharmaceutical market.